Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ...

China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen ...

Mainz Biomed (MYNZ) announced it has entered into a License and Option Agreement with Liquid Biosciences to access a portfolio of novel mRNA ...

Orange Biomed said there is a need for more accurate diabetic testing in Black people and other minorities and the company ...

Patten will also serve as the Head of Global Alliance and lead efforts to manage and strengthen the company’s partner network ...

Harbour BioMed launches Élancé Therapeutics to advance next-generation obesity therapies: Cambridge, Massachusetts Thursday, March 13, 2025, 18:00 Hrs [IST] Harbour BioMed, a gl ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...

Impact BioMedical, Inc. ( ($IBO) ) has shared an update. On March 11, 2025, Impact BioMedical, Inc. appointed Mr. Chan Heng Fai Ambrose as a ...

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Get Free Report)’s share price traded up 3.4% on Friday . The company traded as high as $4.35 and last traded at $4.23. 38,786 shares traded hands during ...

BERKELEY, Calif. - Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company with a market capitalization of $16.47 million, has entered into an exclusive licensing agreement with ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 11, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global ...